Based on the data in the noted references, the panel consensus was to include the fine-particle formulation of abiraterone in combination with methylprednisolone as an option for the treatment of men with N1 or M1 castration-naïve prostate cancer. This is a category 2B recommendation.


### PROS-15, -16, -17

Internal request: In response to the FDA approval of the new fine-particle formulation of abiraterone used in combination with methylprednisolone for the treatment of men with M1 castration-resistant prostate cancer, the panel should vote on its inclusion as an option in this setting.

Based on the data in the noted references, the panel consensus was to include the fine-particle formulation of abiraterone in combination with methylprednisolone as an option for the treatment of men with M1 castration-resistant prostate cancer. This is a category 2A recommendation.
